What is the Wegovy oral dose schedule for weight loss?

Why does the dose start so low if 25 mg is the target?

The 1.5 mg starting dose has one job: keeping side effects manageable while your body adjusts to semaglutide. Nausea, loose stools and indigestion are the most commonly reported effects in trial data, and they are most noticeable when the medicine is first introduced or when the dose steps up. Starting low and moving slowly (a minimum of four weeks at each level) significantly reduces the chance that early discomfort derails treatment before it has had time to work.

A common misconception is that the starter dose is doing nothing useful. That is not quite right. Appetite suppression begins well before the maintenance dose, and gradual titration lets the prescriber assess how well you are tolerating each level. The OASIS 4 trial, which informed the MHRA's approval, reported that most gastrointestinal effects were mild to moderate and transient, not a reason to stop, but worth managing carefully.

Stepping up is a clinical decision, not an automatic one. If a particular dose is causing significant discomfort, a prescriber may suggest staying at that level for longer before moving on. That flexibility is part of why understanding the full Wegovy tablet dose structure before you start is worth the time.

What does taking the tablet correctly actually involve?

The absorption mechanism for oral semaglutide is sensitive to what is in your stomach. The tablet is co-formulated with an absorption enhancer called SNAC, and it only works as intended when the stomach is empty and the volume of liquid is small. The routine is straightforward in principle: wake up, take the tablet with no more than about 120 ml of plain water (a small glass, not a full pint) then wait at least 30 minutes before coffee, breakfast, other medicines or anything else by mouth.

That waiting period catches people out more than the tablet itself does. The NHS tirzepatide and semaglutide guidance pages flag drug absorption as a relevant consideration for oral GLP-1 medicines, and for the Wegovy tablet specifically, the NHS semaglutide medicine guide is a useful first reference for how the medicine is used day to day.

One practical upside: the tablet requires no refrigeration. Store it at room temperature, away from heat and direct light. For people who travel regularly or find pen storage inconvenient, that is a genuine quality-of-life difference. If you want to understand how the semaglutide oral dose is structured and how it compares to injection formats, that page covers the evidence side by side.

Who does this dose schedule apply to, and are there exceptions?

The licensed dose schedule (1.5 mg to 25 mg) applies to adults with a BMI of 30 or above, or a BMI from 27 upward where at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea is present. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; the prescriber reviews the full picture.

The one exception to starting at 1.5 mg is for people already established on the 2.4 mg Wegovy injection. Those patients may, after clinical assessment, begin directly at the 25 mg tablet rather than repeating the full escalation. This is not a self-referral shortcut, it requires a prescriber to confirm the switch is appropriate, check for any change in medical history and review any medicines that might interact.

Wegovy tablets are not licensed for use in pregnancy, breastfeeding or by anyone trying to conceive. They are also not licensed for under-18s. If any of those circumstances apply, a prescriber will discuss alternatives. The tablet is not recommended for people with a history of certain gastrointestinal conditions or medullary thyroid carcinoma, again, points the prescriber covers during assessment. You can read about what that assessment involves on our about us page.

How does the 25 mg maintenance dose compare to what the trial evidence showed?

The OASIS 4 phase-3 trial (307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks) reported an average weight reduction of around 13.6% versus roughly 2.4% on placebo. Among participants who adhered fully to treatment, the figure rose to approximately 17%. That second number is sometimes quoted without the adherence context; it is worth knowing the distinction. If you want to understand how the semaglutide oral dose for weight loss is designed to work across the titration schedule, that page sets out the evidence clearly. The patient experience evidence around oral semaglutide gives a more grounded picture of what real-world adherence looks like.

The 25 mg maintenance dose is meaningfully higher than anything in the Wegovy injection range, which tops out at 2.4 mg weekly or 7.2 mg with the newer single-dose pen. The oral and injectable forms are not directly comparable by number alone (bioavailability differs substantially between routes) but 25 mg is calibrated to deliver a therapeutic level of semaglutide exposure broadly in line with the higher injection doses.

For context on how cost plays into choosing a format, the Wegovy tablet price guide covers what private treatment typically involves. The Wegovy tablet is available on a private prescription only; there is currently no NHS pathway. If you are exploring options, a good starting point is understanding all UK-licensed weight-loss treatments before settling on one.

A prescriber at nume personally reviews every consultation the same day, not software, not an automated queue. If the Wegovy tablet looks like a reasonable fit based on your health details, the next step is a free consultation with our clinical team.